Von Hippel-Lindau Syndrome Clinical Trial
Official title:
A Phase II Trial of Pazopanib in Von Hippel-Lindau Syndrome
This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with von Hippel-Lindau syndrome. Pazopanib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
PRIMARY OBJECTIVE: I. Evaluate safety and efficacy of treatment with pazopanib hydrochloride (pazopanib) for 6 months in patients with von Hippel-Lindau syndrome (VHL) who have a measurable VHL related lesion. SECONDARY OBJECTIVES: I. Evaluate rate of growth over time in target lesions before and after pazopanib treatment. II. Evaluate need for surgical intervention over time in patients who receive pazopanib and compare to rate prior to receipt of drug. III. Create an annotated tissue resource from patients with VHL for use in future research related to cancer. PRECLINICAL OBJECTIVES: I. Evaluate circulating factors in patients with VHL undergoing treatment with pazopanib. II. Evaluate relationship between VHL genotype and response to pazopanib. OUTLINE: Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28. Treatment repeats every 4 weeks for up to 24 weeks in the absence of disease progression or unacceptable toxicity. Patients benefitting from treatment may continue pazopanib hydrochloride in the absence of disease progression. After completion of study treatment, patients are followed up at 30 days and then every 3 months for up to 24 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01967537 -
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
|
Phase 2 | |
| Terminated |
NCT01266070 -
TKI 258 in Von Hippel-Lindau Syndrome (VHL)
|
Phase 2 | |
| Terminated |
NCT00673816 -
Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome
|
Phase 1/Phase 2 | |
| Terminated |
NCT00330564 -
Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
|
Phase 2 | |
| Terminated |
NCT03001349 -
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
|
Early Phase 1 | |
| Recruiting |
NCT01496625 -
National Eye Institute Biorepository for Retinal Diseases
|
||
| Completed |
NCT02859441 -
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
|
Phase 1/Phase 2 | |
| Completed |
NCT00075348 -
Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome
|
N/A | |
| Completed |
NCT00089765 -
Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
|
Phase 1 |